Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Shares Up 4.4%

Shares of Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) shot up 4.4% during trading on Friday . The stock traded as high as $0.90 and last traded at $0.71, 19,472 shares traded hands during mid-day trading. A decline of 90% from the average session volume of 196,095 shares. The stock had previously closed at $0.68.

Separately, Maxim Group began coverage on shares of Navidea Biopharmaceuticals in a research report on Thursday. They issued a “buy” rating and a $2.00 target price for the company.

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) last posted its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.24) EPS for the quarter. The business had revenue of $0.14 million for the quarter.

In other news, major shareholder John K. Jr. Scott acquired 4,000,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 18th. The stock was acquired at an average cost of $0.75 per share, with a total value of $3,000,000.00. Following the acquisition, the insider now owns 5,113,078 shares in the company, valued at $3,834,808.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last ninety days, insiders have purchased 4,011,300 shares of company stock valued at $3,018,490.

A hedge fund recently raised its stake in Navidea Biopharmaceuticals stock. Virtu Financial LLC raised its stake in Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) by 94.1% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 186,972 shares of the biopharmaceutical company’s stock after purchasing an additional 90,647 shares during the period. Virtu Financial LLC owned approximately 0.09% of Navidea Biopharmaceuticals worth $26,000 as of its most recent SEC filing.

About Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment.

Recommended Story: Why do companies pay special dividends?

Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with's FREE daily email newsletter.